Arcturus Therapeutics price target raised to $48 from $41 at BTIG
BTIG raised the firm’s price target on Arcturus Therapeutics (ARCT) to $48 from $41 and keeps a Buy rating on the shares. The Kostaive ...
Arcturus Therapeutics’ (ARCT) “Buy” Rating Reaffirmed at HC Wainwright
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $63.00 price ...
PMLiVE1d
EC approves CSL/Arcturus’ self-amplifying mRNA COVID-19 vaccine Kostaive
Jonathan Edelman, senior vice president of CSL’s vaccines innovation unit, said the approval “marks a significant milestone” ...
GlobalData on MSN11h
Japan’s MHLW approves CSL Behring’s Andembry to stop HAE attacks
CSL Behring KK has gained approval from Japan's Ministry of Health, Labour and Welfare (MHLW) to manufacture and market ...
The Pharma Letter6d
EC approves CSL and Arcturus’ Kostaive
The European Commission has granted marketing authorization for Kostaive (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, ...
Weekly Roundup: 15 Health Press Releases You Need to See
With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...
24/7 Wall St3d
Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc is a biotechnology firm based in San Diego, California, specializing in the development of innovative mRNA medicines and vaccines. With a focus on addressing ...
The Pharma Letter5d
The week in pharma: action, reaction and insight – week to February 14
Significant research news last week included a setback for Pliant Therapeutics, when it paused a Phase IIb trial of its bexotegrast in idiopathic pulmonary fibrosis (IPP). Also, US biotech AnaptysBio ...